Drug Profile
Research programme: therapeutic antibodies - Adimab/GlaxoSmithKline
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Adimab; GlaxoSmithKline
- Developer Adimab; GSK
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified